It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...

TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...